Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01836094 · ClinicalTrials.gov registry record · Early Phase 1
Effects of USP Methylene Blue on Cognitive and fMRI Brain Activity
A Early Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
NCT01836094 is a Early Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 36 participants.
The verdict
NCT01836094, a Early Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate whether low-dose USP methylene blue (MB) will: i) improve short-term memory retention in a delayed match-to-sample task, ii) reduce reaction time in a psychomotor vigilance test, and iii) enhance responses to a visual-motor task as measured by functional magnetic resonance imaging (fMRI). A single low-dose MB or placebo will be orally administered to self-declared healthy adults using double-blind study design. Non-invasive fMRI data will be acquired before and after MB administration in the same subjects. Each study will take 2-3 hours, inclusive of an hour break in between.
Interventions
- DRUG Placebo
- DRUG Methylene Blue (USP grade, 280mg oral)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01836094
The ClinicalTrials.gov registry entry for NCT01836094 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01836094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01836094 about?
NCT01836094 is a clinical study titled "Effects of USP Methylene Blue on Cognitive and fMRI Brain Activity". The purpose of the study is to evaluate whether low-dose USP methylene blue (MB) will: i) improve short-term memory retention in a delayed match-to-sample task, ii) reduce reaction time in a psychomotor vigilance test, and iii) enhance responses to a visual-motor task as measured by functional magne...
What is the current status of trial NCT01836094?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2013-08. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01836094?
The interventions under investigation include: Placebo (DRUG), Methylene Blue (USP grade, 280mg oral) (DRUG).
Who is sponsoring clinical trial NCT01836094?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.